b'Medicine & ResearchThrower -One in seven American adults isworsened MS symptoms and an acceleration affected by migraine headaches, includingof MS progression. Glucagon-like peptide-1 those living with MS. A newer class of migraineagonists represent a newer class of drugs in preventativetherapiesistheanti-CGRPthe ght against obesity. Examples of glucagon-monoclonal antibodies. Most of these arelike peptide-1 agonists include: administered as once-monthly subcutaneous Dulaglutide (Trulicity): A once-weekly injections to reduce the frequency and severityinjection for adults and children 10 and of migraine headaches. Some of our moreolder highly effective MS therapies are also mAbs. Exenatide (Byetta): An injectable suspension These include the B-cell depleting therapies Exenatide extended release (Bydureon (Rituximab, Ocrevus, Kesimpta, and Briumvi)BCise): An injectable suspension and Tysabri. Can mAbs for migraine prevention be used by those on an MS mAb? Yes. This study, Liraglutide (Victoza): An injectable solution combined with real-world experience, showswith a starting dose of .6 mg once daily that these different classes of mAbs are used Lixisenatide (Adlyxin): An injectable together in a person with MS. The study alsosolution with a starting dose of 10 mcg looked at non-mAb DMTs for MS and showedonce daily no safety concerns with those combinations.Semaglutide (Ozempic): An injectable Weight loss drugs safe for people with MSsolution Researchers at Beth Israel Deaconess Medical Semaglutide tablets (Rybelsus): A pill Center, Harvard Medical School, studied thetaken by mouth once a day safetyandeffectivenessofglucagon-like Tirzepatide (Mounjaro): A once-weekly peptide-1medicationsinpeoplewithMS.injection The study included 60 people with MS who Albiglutide: A GLP-1 dimer fused to used GLP-1 medications between 2006 andhuman albumin 2024. Results showed an average body massMany of those living with MS have asked indexreductionof3.7percentandan8.1whether these drugs can be used safely by the ng/mL increase in vitamin D levels. ThereMS community. Yes, GLP-1 drugs, as shown were no hospitalizations or deaths, and MSby this study, are safe and effective for those disability scores remained stable. Only onewith MS. GLP-1 agonists have been shown to patient had a relapse, and one showed newhave anti-inammatory effects in the CNS. At MRI activity. The study concluded that GLP-1this point, research has not shown whether this medications are safe for people with MS andwould lead to an MS disease-modulating benet.may support weight loss and vitamin D levels.Study: Extended-interval dosing Thestudy waspublishedinthejournal Multiple sclerosis and related disorders.for Ocrevus may improve safetyThrower- One in three Americans areResearchers at Dow University of Health overweight. Two in five Americans are obese. Sciences, Karachi, conducted a systematic This may be especially problematic for thosereview and meta-analysis comparing extended living with MS. Studies have shown that obesityinterval dosing and standard-interval dosing of is linked to a higher risk for developing MS,ocrelizumab in MS patients. The study analyzed msfocusmagazine.org 44'